These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 30076955

  • 21. Drug disposition in cystic fibrosis.
    Rey E, Tréluyer JM, Pons G.
    Clin Pharmacokinet; 1998 Oct; 35(4):313-29. PubMed ID: 9812180
    [Abstract] [Full Text] [Related]

  • 22. Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.
    Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, Tao X, Höhl R, Holzgrabe U, Kees F, Stephan U, Sörgel F.
    Pharmaceutics; 2019 Jun 18; 11(6):. PubMed ID: 31216743
    [Abstract] [Full Text] [Related]

  • 23. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.
    Naber KG, Theuretzbacher U, Kinzig M, Savov O, Sörgel F.
    Antimicrob Agents Chemother; 1998 Jul 18; 42(7):1659-65. PubMed ID: 9661000
    [Abstract] [Full Text] [Related]

  • 24. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ, Wise R, Kirkpatrick B, Ashby JP.
    J Antimicrob Chemother; 1988 Oct 18; 22 Suppl D():191-4. PubMed ID: 3144537
    [Abstract] [Full Text] [Related]

  • 25. Fleroxacin pharmacokinetics in patients with liver cirrhosis.
    Blouin RA, Hamelin BA, Smith DA, Foster TS, John WJ, Welker HA.
    Antimicrob Agents Chemother; 1992 Mar 18; 36(3):632-8. PubMed ID: 1622175
    [Abstract] [Full Text] [Related]

  • 26. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
    Nakashima M, Kanamaru M, Uematsu T, Takiguchi A, Mizuno A, Itaya T, Kawahara F, Ooie T, Saito S, Uchida H.
    J Antimicrob Chemother; 1988 Oct 18; 22 Suppl D():133-44. PubMed ID: 3144532
    [Abstract] [Full Text] [Related]

  • 27. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM, Coker HA, Oduola AM, Ifudu ND, Sowunmi A.
    Chemotherapy; 1998 Oct 18; 44(6):369-76. PubMed ID: 9755295
    [Abstract] [Full Text] [Related]

  • 28. Population pharmacokinetics of ciprofloxacin in pediatric patients.
    Rajagopalan P, Gastonguay MR.
    J Clin Pharmacol; 2003 Jul 18; 43(7):698-710. PubMed ID: 12856383
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.
    Bertino JS, Nafziger AN.
    Antimicrob Agents Chemother; 1996 Mar 18; 40(3):789-91. PubMed ID: 8851614
    [Abstract] [Full Text] [Related]

  • 30. Influence of rifampin on fleroxacin pharmacokinetics.
    Schrenzel J, Dayer P, Leemann T, Weidekamm E, Portmann R, Lew DP.
    Antimicrob Agents Chemother; 1993 Oct 18; 37(10):2132-8. PubMed ID: 8257135
    [Abstract] [Full Text] [Related]

  • 31. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I, Van Hecken A, Verbesselt R, Tjandra-Maga TB, De Schepper PJ.
    J Antimicrob Chemother; 1988 Aug 18; 22(2):197-202. PubMed ID: 3141343
    [Abstract] [Full Text] [Related]

  • 32. Overview of the pharmacokinetics of fleroxacin.
    Nightingale CH.
    Am J Med; 1993 Mar 22; 94(3A):38S-43S. PubMed ID: 8452184
    [Abstract] [Full Text] [Related]

  • 33. Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.
    Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H.
    Antimicrob Agents Chemother; 1993 Feb 22; 37(2):293-6. PubMed ID: 8452360
    [Abstract] [Full Text] [Related]

  • 34. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.
    Reigner BG, Welker HA.
    Antimicrob Agents Chemother; 1996 Mar 22; 40(3):575-80. PubMed ID: 8851573
    [Abstract] [Full Text] [Related]

  • 35. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
    Taburet AM, Devillers A, Thomare P, Fillastre JP, Veyssier P, Singlas E.
    Clin Pharmacokinet; 1990 Jul 22; 19(1):80-8. PubMed ID: 2116257
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
    Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, Schaad UB.
    Antimicrob Agents Chemother; 1996 Jan 22; 40(1):29-34. PubMed ID: 8787874
    [Abstract] [Full Text] [Related]

  • 37. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG.
    Clin Pharmacokinet; 2006 Jan 22; 45(11):1099-114. PubMed ID: 17048974
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019.
    De Sutter PJ, Gasthuys E, Van Braeckel E, Schelstraete P, Van Biervliet S, Van Bocxlaer J, Vermeulen A.
    Clin Pharmacokinet; 2020 Dec 22; 59(12):1551-1573. PubMed ID: 32808233
    [Abstract] [Full Text] [Related]

  • 39. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.
    Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M, Sörgel F.
    Br J Clin Pharmacol; 2010 Feb 22; 69(2):167-78. PubMed ID: 20233180
    [Abstract] [Full Text] [Related]

  • 40. Cloxacillin absorption and disposition in cystic fibrosis.
    Spino M, Chai RP, Isles AF, Thiessen JJ, Tesoro A, Gold R, MacLeod SM.
    J Pediatr; 1984 Nov 22; 105(5):829-35. PubMed ID: 6502318
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.